Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Newron Pharmaceuticals SpA

  • Stefan Weber, Newron Pharmaceuticals SpA

Newron is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The company is headquartered in near Milan, Italy. Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the EU, Switzerland and the USA, and is commercialized by its Partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago®/safinamide for PD, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including Sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

  • Date:Monday, February 11
  • Time:2:15 PM - 2:30 PM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
  • Submission ID:23283
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:investor
  • Company Website:www.newron.com
  • Company HQ City:Bresso (Milan)
  • Company HQ Country:Italy
  • Ticker:NWRN
  • Exchange:SIX
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:sarizotan
  • Development Phase of Primary Product:Phase III
Speakers
Stefan Weber
Newron Pharmaceuticals SpA
Back